FFA
GTBP icon

Farther Finance Advisors’s GT Biopharma GTBP Stock Holding History

Farther Finance Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47K Hold
120
– – ﹤0.01% 5265
2026
Q1 		$1.23K Hold
120
– – ﹤0.01% 5047
2025
Q4 		$2.36K Buy
+120
New +$2.13K ﹤0.01% 4627
2025
Q2 		– Hold
0
– -$14 – 4560
2025
Q1 		– Hold
0
– – – 4208
2024
Q4 		– Hold
0
– – – 3938

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Farther Finance Advisors's GTBP Position: Q2 2026 in Review

Farther Finance Advisors held its GT Biopharma (GTBP) position steady in Q2 2026 at 120 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #5265.

Farther Finance Advisors first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.36K in Q4 2025. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Farther Finance Advisors held 120 shares of GT Biopharma worth $1.47K as of Q2 2026.
  • Farther Finance Advisors left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5265 holding.
  • Farther Finance Advisors first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Farther Finance Advisors's GT Biopharma position peaked at $2.36K in Q4 2025.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.